Biggest slice of revenue most likely attributed to Myeloma Fibrosis. The issue Incyte probably have concern with is that wherever the Jakavi pathway has some success, so will MSCs. But more to the point, MSCs are a cure whereas Jak Inhibitors are simply an ongoing treatment.
Cell Therapy News/Articles, page-16454
-
- There are more pages in this discussion • 1,576 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |